Melatonin Immune Boost COVID 19 Study
Phase 4
- Registration Number
- CTRI/2020/06/025613
- Lead Sponsor
- Rohit Walia
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
High groups for COVID 19 related disease
Elderly : age > 60 years
Diabetes
Obesity
Heart Failure
Immuno supressed patients
Exclusion Criteria
Chronic Renal Failure
Chronic Hepatic Failure
Any hospitalisation for past 3 months
Any recent vaccination
Nutrition supplements
Any addiction
Chronic infections live Human immunodeficiency disorder , Hepatitis B,C., etc
Any autoimmune disease
Irregular sleep pattern
Primary immunodeficiency states
Vitamin deficiency states
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SARS-CoV 2 infection rate : Number of confirmed (positive CRP) symptomatic infections in each treatment group <br/ ><br>Timepoint: 8 weeks
- Secondary Outcome Measures
Name Time Method <br/ ><br>Frequency of respiratory tract infections during course of study using the â?¨Wisconsin Upper Respiratory Symptom Survey <br/ ><br>Timepoint: 8 weeks;Change from baseline immune cells and markers after 8 weeks of medications <br/ ><br>Timepoint: 8 weeks;Number of participants with treatment-related adverse eventsTimepoint: 8 weeks